USO vs XBI
United States Oil Fund vs SPDR S&P Biotech ETF
USO$134.97
United States Oil Fund
Tracks WTI crude oil futures.
Expense: 0.86%Yield: 0.00%
XBI$133.66
SPDR S&P Biotech ETF
Equal-weight biotech stocks in the S&P Biotech Index.
Expense: 0.35%Yield: 0.34%
Quick take
- • XBI has the lower expense ratio at 0.35% vs 0.86% for USO.
- • XBI pays a higher dividend yield (0.34%).
Side-by-side metrics
| Metric | USO | XBI |
|---|---|---|
Expense ratio Annual fee. Lower is better. | 0.86% | 0.35% |
Dividend yield Trailing 12-month yield. | 0.00% | 0.34% |
AUM Assets under management — bigger funds are typically more liquid. | $1.94B | $8.30B |
YTD return | 93.68% | 12.92% |
1-year return | — | — |
3-year return Annualized. | — | — |
5-year return Annualized. | — | — |
10-year return Annualized. | — | — |
Beta (3Y) Volatility relative to the market. Closer to 1 = market-like. | 2.14 | 1.09 |
P/E ratio | 40.84 | — |
Last price | $134.97 | $133.66 |
Inception | — | — |
Issuer | USCF | State Street |
USO top holdings
Holdings data unavailable for USO.
XBI top holdings
Top holdings · XBI
| APLS | Apellis Pharmaceuticals Inc | 1.87% |
| RVMD | Revolution Medicines Inc Ordinary Shares | 1.65% |
| TVTX | Travere Therapeutics Inc Ordinary Shares | 1.62% |
| ARWR | Arrowhead Pharmaceuticals Inc | 1.44% |
| TWST | Twist Bioscience Corp | 1.42% |
| SMMT | Summit Therapeutics Inc Ordinary Shares | 1.40% |
| ALKS | Alkermes PLC | 1.38% |
| TGTX | TG Therapeutics Inc | 1.37% |
| MDGL | Madrigal Pharmaceuticals Inc | 1.36% |
| BEAM | Beam Therapeutics Inc | 1.32% |
Sector breakdown · XBI
Financial Services0.2%
Healthcare99.8%
About USO
USO (United States Oil Fund) is Tracks WTI crude oil futures. Managed by USCF, the fund carries $1.9B in assets under management, an expense ratio of 0.86%.
About XBI
XBI (SPDR S&P Biotech ETF) is Equal-weight biotech stocks in the S&P Biotech Index. Managed by State Street, the fund carries $8.3B in assets under management, an expense ratio of 0.35%, a dividend yield of 0.34%. Its largest holding is Apellis Pharmaceuticals Inc (APLS), which represents 1.9% of the portfolio. Financial Services is the fund's largest sector exposure at 0.2%.